In a proof-of-concept study, Stella E. Lee, MD, director of the Sinus Center in the Division of Otolaryngology–Head & Neck Surgery at Brigham and Women’s Hospital, and colleagues demonstrated a safe, portable, objective method for measuring smell function and its relationship with cognitive processing.

Christopher D. Dwyer, MD, Thomas L. Carroll, MD, and colleagues present the first publication to describe the use of Silk–HA (Silk Voice) for augmenting vocal fold tissue for phonation improvement in patients, including clinical pearls and suggestions for the informed consent process.

Thomas L. Carroll, MD, director of the Voice Program at Brigham and Women’s Hospital, and colleagues have developed the first classification of laryngopharyngeal reflux severity that stratifies patients based on the impact of their symptoms on quality of life.

For years, patients with chronic rhinosinusitis (CRS) and nasal polyps had few treatment options beyond topical corticosteroids and surgery. Stella Lee, MD, director of the Brigham Sinus Center, conducted trials of three biologic therapies showing signs of addressing CRS symptoms and improving patient quality of life.

In two high-definition larynx models, Chan and colleagues recently demonstrated that side-firing laser fibers may substantially increase endoscopic access to difficult lesions. Now, researchers at Brigham and Women’s Hospital have built on that work, corroborating the results in additional, more varied anatomic models.

Thomas L. Carroll, MD, section chief of Laryngology and director of the Voice Program at Brigham and Women’s Hospital, and colleagues recently completed a Delphi process to develop guidance about treating laryngopharyngeal reflux disease (LPR). They report their consensus.

Ashley L. Miller, MD, a resident in the Division of Otolaryngology–Head and Neck Surgery at Brigham and Women’s Hospital, and colleagues demonstrated that VESPA can identify patients scheduled for major otolaryngologic head and neck surgery who are at risk of delayed or complex discharge.

Stella E. Lee, MD, of the Division of Otolaryngology–Head & Neck Surgery at Brigham and Women’s Hospital, and colleagues speculate that global IL-4Rα inhibition could have immune consequences. In a research note, they report preliminary data on how targeting IL-4Rα with dupilumab changes the local inflammatory milieu.